相关实验视频

Updated: May 21, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

基于乌拉的本佐酸和衍生物的QSAR和分子对接研究,以探索新型二基-4抑制剂

Pradeep Pilania¹, Prithvi Singh²

¹Department of Chemistry, Government Science College, Sikar-332 001, Rajasthan, India.

Current pharmaceutical design

|March 19, 2025

概括

这项研究开发了新的基于乌拉的化合物,作为2型糖尿病的二二酶-4 (DPP-4) 抑制剂. QSAR和对接分析确定了进一步优化的有力候选者.

科学领域:

药用化学医学化学
计算化学的计算化学
药理学药理学是指药理学的学科.

背景情况:

糖尿病 (DM),特别是2型糖尿病 (T2DM),是一个重要的全球健康问题.
双基化酶-4 (DPP-4) 抑制剂是T2DM管理中的关键类型的降血糖药物.

研究的目的:

设计和识别基于 uracil 的新型酸和衍生物作为强大的 DPP-4 抑制剂.
为药物发现整合定量结构-活性关系 (QSAR) 和分子对接研究.

主要方法:

使用比较分子场分析 (CoMFA) 和部分最小平方 (PLS) 回归进行定量结构-活动关系 (QSAR) 建模.
对QSAR模型的内部和外部验证,包括适用性领域分析.
使用Autodock 4.2对抗DPP-4蛋白质的分子对接模拟 (PDB ID: 2RGU).

主要成果:

开发了一个强大的QSAR模型,具有很高的预测精度 (r2 测试=0.715,Q2 LOO=0.797,Q2 L5O=0.809).
对接研究显示,在DPP-4活性部位内设计的化合物具有显著的结合潜力.
确定了四种具有预测对DPP-4的高抑制活性的新型同源.

结论:

该研究成功地确定了用于DPP-4抑制的基于 uracil 的有希望的支架.
这些新型化合物显示出开发更多选择性,强效和生物可用DPP-4抑制剂的潜力,用于T2DM治疗.
建议进一步优化这些支架,以推进它们的治疗应用.

关键词:

多重线性回归的组合协议 (CP-MLR)部分最小平方 (PLS) 和适用域 (AD).定量结构与活动关系 (QSAR)龙形容器的描述器

更多相关视频

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...